BioPharmSignal logoBioPharmSignal

Biotech News

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)

Lyra Therapeutics (LYRA)Lyra TherapeuticsClinical readout

ENLIGHTEN 2 trial met primary endpoint with LYR-210 demonstrating statistically significant improvement in the composite of the three cardinal symptoms (3CS) of CRS at 24 weeks (p=0.0078) ENLIGHTEN 2 trial also showed statistically significant improvement in key secondary endpoints in the full

Related news

LYRALyra Therapeutics2025-05-07 11:00 EST

Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025

LYRALyra Therapeutics2025-10-06 11:00 EST

Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study

View all latest news

Lyra Therapeutics

Lyra Therapeutics is an otolaryngology company focused on chronic rhinosinusitis and upper-airway disease. Its platform uses localized delivery to treat difficult ENT conditions.

Recent company news

LYRALyra Therapeutics2026-04-17 12:00 EST

Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC

LYRALyra Therapeutics2026-01-12 12:00 EST

Lyra Therapeutics Provides Corporate Update

LYRALyra Therapeutics2025-11-12 21:01 EST

Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

LYRALyra Therapeutics2025-10-06 11:00 EST

Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study

LYRALyra Therapeutics2025-08-12 20:01 EST

Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Stock data

Close
0.01 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States